A Hurel video case study
Clarinex®: The Hunt for the Unproducible Metabolite
Ronald E. White, Ph.D., President, White Global Pharma Consultants, LLC
Formerly Vice President of Drug Metabolism, Schering-Plough Research Institute, Dr. White was directly engaged in the pre-clinical development of desloratadine (Clarinex®), the second-generation drug that Schering developed to follow its blockbuster medication, loratadine (Claritin®). Dr. White’s case study traces the research challenges Schering faced in attempting to answer the FDA’s questions about 3-hydroxy desloratadine, a circulating metabolite which in vitro models then available to Schering were unable to generate but which the HµRELhumanTM model was shown to produce successfully. It also comments on how a correctly predictive in vitro tool like Hurel might have affected the economics of the commercial launch of Clarinex®. The video runs about four minutes. A downloadable white paper printed version is also available.

multi-readout, repeat-dose
DILI screening
DILI screening

Hurel microlivers afford better prediction than 3D

Toxicology Research
Long-enduring infectious liver disease platform
Toxicity Ratios*
A new marker for hepatotoxic chronicity

*patent pending
a new, patent-pending
efflux transport
assay method
Superior intrinsic clearance
and biotransformation of
low-turnover drugs